Perrigo’s Record OTC Sales Tempered By Rising Costs Of Doing Business
• By Elizabeth Crawford
Record OTC drug sales helped boost Perrigo's revenue 29 percent in its latest earnings period, but the rising costs of doing business dragged down margins and forced the company to lower its fiscal 2009 earnings guidance
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Pink Sheet for daily insights
